PTO/SB/05 (05-03)

Approved for use through 04/20/2020. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DePARTMENT OF COMMENT
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMENT
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information underst displayes a wall Office control number. Attorney Docket No. 01371/2/US LITH ITY K Inoc Firet Inventor PATENT APPLICATION Title SELECTIVE CYCLOOXYGENASE-2 INHIBITOR TRANSMITTAL Express Mail Label ER 078630477 US visional applications under 37 CER 1 53(h)) APPLICATION ELEMENTS Mail Stop Patent Application ADDRESS TO: P. O. Box 1450 See MPEP chapter 600 concerning utility patent application contents. Alexandria VA 22313-1450 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or 17497 U.S.PTC 10/683623 (Submit an original, and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Computer Readable Form (CRF) \mathbf{J} Specification [Total Pages 53 (preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention i. CD-ROM or CD-R (2 copies): or - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D ii. Paper - Reference to sequence listing, a table. or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(e) 37 CFR 3.73(b) Statement 10 Power of Attorney - Abstract of the Disclosure (when there is an assignee) English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) | Total Sheets Information Disclosure Statement (IDS)/PTO-1449 Coniec of IDS 12 Oath or Declaration ITotal Pages 13 Preliminary Amendment Newly executed (original or copy) Return Receipt Postcard (MPEP 503) J (Should be specifically itemized)
Certified Copy of Priority Document(s) Copy from a prior application (3/ CFR 1.63(d)) (for continuation/divisional with Box 18 completed) 15 (if foreign priority is claimed) DELETION OF INVENTOR(S) Nonnublication Request under 35 U.S.C. 122 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 Signed statement attached deleting inventor(s) or its equivalent. named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

Other: Application Data Sheet. See 37 CFR 1.76 If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76 Continuation Divisional Continuation-in-part (CIP) of prior application No.:

Examiner _ Group / Art Unit: Prior anniication information: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted apict on parts. 19. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label or X Correspondence address below 26648 (Insert Customer No. or Attach bar code label here) PHARMACIA CORPORATION Name Global Patent Department 575 Maryville Centre Drive Address Mail Zone 1006 Zip Code 63141 MO Citv St. Louis Telephone 314-274-6812 314-274-9095 II S A Country

Registration No. (Attorney/Agent) Name (Print/Type) James C. Forbes 39,457 James C 70 rbe October 10, 2003 Signature Date

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an apprication. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete. including gathering, preparing, and ubmitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.										
FEE TRANSMITTA	П	Complete if Known								
	-	Application Number			Unknown					
for FY 2003	ı	Filing Date			October 10, 2003					
Effective 01/01/2003. Patent fees are subject to annual revision	n. T	First Named Inventor			K. Inoo					
Applicant claims small entity status. See 37 CFR 1.27			niner N	lame	Unknown					
		Group Art Unit			Unknown					
TOTAL AMOUNT OF PAYMENT (\$) \$896	.00 Attorney Docket No.				No. 01371/2/US					
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)									
Cheek Conditioned Money Other None	3. ADDITIONAL FEES									
Deposit Account:	Large I		Small Fee	Entity						
Deposit	Code	(\$)	Code	(\$)	Fee Description Fee Paid					
Account Number 19-1025	1051	130	2051		Surcharge - late filling fee or oath					
Deposit Account Name Pharmacia Corporation		50	2052	25	Surcharge - late provisional filing fee or cover sheet					
		130	1053	130	Non - English specification					
The Commissioner is authorized to: (check all that apply)		2,520	1812		For filing a request for ex parte reexamination					
Charge fee(s) indicated below Credit any overpayments		920*	1804		Requesting publication of SIR prior to Examiner action					
Charge any additional fee(s) during the pendency of this application		1,840*	1805	1.840*	Requesting publication of SIR after Examiner action					
Charge fee(s) indicated below, except for the filing fee		110	2251		Extension for reply within first month					
to the above-identified deposit account.	1252	410	2252	205	Extension for reply within second month					
FEE CALCULATION	1253	930	2253	465	Extension for reply within third month					
Large Entity Small Entity	1254	1,450	2254	725	Extension for reply within tourtn montin					
Fee Fee Fee Fee Description	1255	1,970	2255	985	Extension for reply within fifth month					
Code (\$) Code (\$) Fee Paid 1001 750 2001 375 Utility filing fee 770.00	1401	320	2401	160	Notice of Appeal					
1002 330 2002 165 Design filing	1402	320	2402	160	Filing a brief in support of an appeal					
1003 520 2003 260 Plant filing fee	1403	280	2403	140	Request for oral hearing					
1004 750 2004 375 Reissue filing	1451	1,510	1451	1,510	Petition to institute a public use proceeding					
1005 160 2005 80 Provisional filing fee	1452	110	2452	55	Petition to revive - unavoidable					
SUBTOTAL (1) (\$) \$770.00	1453	1,300	2453	650	Petition to revive - unintentional					
2. EXTRA CLAIM FEES FOR UTILITY AND	1501	1,300	2501	650	Utility issue fee (or reissue)					
Fee from	1502	470	2502	235	Design issue fee					
Extra Claims below Fee Paid	1503	630	2503	315	Plant issue fee					
Total Claims 27 -20** = 7 X 18.00 = 126.00 Independent 3 -3** = 0 X 86.00 = 0.00	1460	130	1460	130	Petitions to the Commissioner					
Claims Multiple Dependent	1807	50	1807		Processing fee under 37 CFR § 1.17(q)					
Large Entity Small Entity	1806	180	1806	180	Submission of Information Disclosure Statement					
Fee Fee Fee Fee Description Code (\$)	8021	40	8021	40						
1202 18 2202 9 Claims in excess of 20	1809	750	2809		Filing a submission after final rejection (37 CFR § 1.129(a))					
1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid	1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))					
1204 84 2204 42 ** Reissue independent claims	1801	750	2801	375	Request for Continued Examination (RCE)					

"or number	reviously paid, if greater, For Reissues, see above					=
SUBMITTE	DBY			Complete (if	applicable)	_
Name (Print/		Registration No. (Attorney/Agent)	39,457	Telephone	847-581-6090	
Signature	James C 701	James C. Forbes				_

WARNING/Information on this form may become public. Credit card information should

Other fee (specify)

over original patent

SUBTOTAL (2)

** Reissue claims in excess of 20 and over original patent

> (\$) \$126.00

not be included on this form. Provide credit card information and authorization on This collection of information is required by 37 CFR.1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 3.5 U.S.C. 122 and 37 CFR.1.1.4. This collection is estimated to take 12 minutes to complete, including pathwing, preparing, and submitting the completed application from the USPTO. Time will vary depending upon the information complete in complete in the common of time year, require to complete in fish from and/or suggestions for reducing in the summon of time year, equive to complete in fish from and/or suggestions for reducing in the summon of time year. The process of the complete in the form and/or suggestions for reducing in the summon of time year. The process of the pr

*Reduced by Basic Filing Fee Paid

1802 900 1802 900 Request for expedited examination of a design application

SUBTOTAL (3) (\$)